Spark Investment Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Spark Investment Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-24,100	Closed	-$130K	–	749
2019 Q1	$130K	Sell	24,100 -75,900	-76%	-$369K	0.01%	550
2018 Q4	$297K	Buy	+100,000	New	+$548K	0.02%	455
2015 Q4	–	Sell	-12,335	Closed	-$176K	–	878
2015 Q3	$176K	Buy	+12,335	New	+$303K	0.02%	555

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spark Investment Management's ZYNE Position: Q2 2019 in Review

Spark Investment Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2019, closing a stake of 24,100 shares — an estimated $130K sold.

Spark Investment Management first reported a position in ZYNE in Q3 2015 and held it in 3 quarters. The position peaked at $297K in Q4 2018. 76 funds tracked by Wall St. Rank hold ZYNE as of Q2 2019.

Spark Investment Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2019 after selling out during the quarter.
Spark Investment Management sold 24,100 Zynerba Pharmaceuticals, Inc shares in Q2 2019, an estimated $130K.
Spark Investment Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2015 and held it in 3 quarters.
Spark Investment Management's Zynerba Pharmaceuticals, Inc position peaked at $297K in Q4 2018.
76 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2019.

Based on Spark Investment Management's 13F filing for Q2 2019, filed 12 Aug 2019.